Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by pericles1on Apr 22, 2010 7:30pm

515 Views

Post# 17021795

News from ONCYv2 board.

Posters seem to think this is positive news, I do not. To me it just means our lung cancer trial continues to enroll slowly and is behind schedule. Maybe Mayo likes what they see in the trial but to be added so late in the trial means we are having trouble rounding up patients!

Mayo is now enrolling patients in the KRas trial. Expect a few more new centers
to join. This will certainly speed up the phase II trial and should be positive
for the future phase III (should they decide to file for an SPA) trial as well.

United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Julian Molina, M.D. 507-284-2511 molina.julian@mayo.edu
Principal Investigator: Julian Molina, M.D.